{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:38:21Z","timestamp":1794569901379,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T00:00:00Z","timestamp":1567987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Berlin Institute of Health","award":["Clinical Scientist Program"],"award-info":[{"award-number":["Clinical Scientist Program"]}]},{"name":"Berlin Institute of Health","award":["Clinical Scientist Program"],"award-info":[{"award-number":["Clinical Scientist Program"]}]},{"name":"Berlin Institute of Health","award":["Clinical Scientist Program"],"award-info":[{"award-number":["Clinical Scientist Program"]}]},{"name":"Berlin Institute of Health","award":["Clinical Scientist Program"],"award-info":[{"award-number":["Clinical Scientist Program"]}]},{"name":"German Eye Cancer Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to date. Whereas unilateral intraocular retinoblastoma is cured by enucleation of the eye, infiltration of the optic nerve indicates potential diffuse scattering and tumor spread leading to a major therapeutic challenge. CAR-T cell therapy could improve the currently limited therapeutic strategies for metastasized retinoblastoma by simultaneously killing both primary tumor and metastasizing malignant cells and by reducing chemotherapy-related late effects.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>CD171 and GD2 expression was flow cytometrically analyzed in 11 retinoblastoma cell lines. CD171 expression and T cell infiltration (CD3<jats:sup>+<\/jats:sup>) was immunohistochemically assessed in retrospectively collected primary retinoblastomas. The efficacy of CAR-T cells targeting the CD171 and GD2 tumor-associated antigens was preclinically tested against three antigen-expressing retinoblastoma cell lines. CAR-T cell activation and exhaustion were assessed by cytokine release assays and flow cytometric detection of cell surface markers, and killing ability was assessed in cytotoxic assays. CAR constructs harboring different extracellular spacer lengths (short\/long) and intracellular co-stimulatory domains (CD28\/4-1BB) were compared to select the most potent constructs.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All retinoblastoma cell lines investigated expressed CD171 and GD2. CD171 was expressed in 15\/30 primary retinoblastomas. Retinoblastoma cell encounter strongly activated both CD171-specific and GD2-specific CAR-T cells. Targeting either CD171 or GD2 effectively killed all retinoblastoma cell lines examined. Similar activation and killing ability for either target was achieved by all CAR constructs irrespective of the length of the extracellular spacers and the co-stimulatory domain. Cell lines differentially lost tumor antigen expression upon CAR-T cell encounter, with CD171 being completely lost by all tested cell lines and GD2 further down-regulated in cell lines expressing low GD2 levels before CAR-T cell challenge. Alternating the CAR-T cell target in sequential challenges enhanced retinoblastoma cell killing.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6131-1","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:03:56Z","timestamp":1568012636000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing"],"prefix":"10.1186","volume":"19","author":[{"given":"Lena","family":"Andersch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Radke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Schwiebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Schumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grunewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Zirngibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Flemmig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rossig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Joussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Henssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Eggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes H.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-5412","authenticated-orcid":false,"given":"Annette","family":"K\u00fcnkele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"6131_CR1","first-page":"1","volume":"1","author":"H Dimaras","year":"2015","unstructured":"Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, Abramson DH, Shields CL, Chantada GL, Njuguna F, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:1\u201322.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"6131_CR2","first-page":"197","volume":"6","author":"SE Soliman","year":"2017","unstructured":"Soliman SE, Racher H, Zhang C, MacDonald H, Gallie BL. Genetics and molecular diagnostics in retinoblastoma--an update. Asia Pac J Ophthalmol (Phila). 2017;6(2):197\u2013207.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"6131_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.26193","volume":"64","author":"P Temming","year":"2017","unstructured":"Temming P, Arendt M, Viehmann A, Eisele L, Le Guin CHD, Sch\u00fcndeln MM, Biewald E, Astrahantseff K, Wieland R, Bornfeld N, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: a report from the German reference center. Pediatr Blood and Cancer. 2017;64:71\u201380.","journal-title":"Pediatr Blood and Cancer"},{"key":"6131_CR4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.ophtha.2007.03.074","volume":"114","author":"DS Gombos","year":"2007","unstructured":"Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, Antoneli CBG, Greenwald M, Haik BG, Leal CA, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma. Is chemotherapy a factor? Ophthalmol. 2007;114:1378\u201383.","journal-title":"Ophthalmol"},{"issue":"06","key":"6131_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1055\/s-0032-1327563","volume":"224","author":"P. Temming","year":"2012","unstructured":"Temming P, Lohmann D, Bornfeld N, Sauerwein W, Goericke SL, Eggert A: Current concepts for diagnosis and treatment of retinoblastoma in Germany: aiming for safe tumor control and vision preservation TT - Aktuelle Konzepte zur diagnose und Behandlung des Retinoblastoms in Deutschland mit dem Ziel der sicheren Tumorkontrolle. Klin Padiatr 2012, 224:339\u2013347.","journal-title":"Klinische P\u00e4diatrie"},{"key":"6131_CR6","first-page":"692","volume":"73","author":"CL Shields","year":"1993","unstructured":"Shields CL, Ja S, Baez K, Cater JR, De Potter P. Choroidal invasion of retinoblastoma: metastatic potential and clinical risk factors. Brit J Opthalmol. 1993;73:692\u20138.","journal-title":"Brit J Opthalmol"},{"key":"6131_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/sj.bmt.1703832","volume":"31","author":"B Kremens","year":"2003","unstructured":"Kremens B, Wieland R, Reinhard H, Neubert D, Beck JD, Klingebiel T, Bornfeld N, Havers W. High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant. 2003;31:281\u20134.","journal-title":"Bone Marrow Transplant"},{"key":"6131_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/1097-0142(20001115)89:10<2117::AID-CNCR12>3.0.CO;2-9","volume":"89","author":"IJ Dunkel","year":"2000","unstructured":"Dunkel IJ, Aledo A, Kernan NA, Kushner B, Bayer L, Gollamudi SV, Finlay JL, Abramson DH. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89:2117\u201321.","journal-title":"Cancer"},{"key":"6131_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","volume":"22","author":"MV Maus","year":"2016","unstructured":"Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res. 2016;22:1875\u201385.","journal-title":"Clin Cancer Res"},{"key":"6131_CR10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","volume":"68","author":"K Newick","year":"2017","unstructured":"Newick K, Brien SO, Moon E, Albelda SM. CAR T cell therapy for solid tumors. Annu Rev Med. 2017;68:139\u201352.","journal-title":"Annu Rev Med"},{"issue":"16","key":"6131_CR11","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med"},{"key":"6131_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, Yang JC, Phan GQ, Hughes MS, Sherry RM, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540\u20139.","journal-title":"J Clin Oncol"},{"key":"6131_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discovery. 2013;3:388\u201398.","journal-title":"Cancer Discovery"},{"issue":"3","key":"6131_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/01.cji.0000161397.96582.59","volume":"28","author":"RD Guest","year":"2005","unstructured":"Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al. The role of extracellular spacer regions in the optimal Design of Chimeric Immune Receptors: evaluation of four different scFvs and antigens. J Immunother. 2005;28(3):203\u201311.","journal-title":"J Immunother"},{"key":"6131_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2326-6066.CIR-14-0127","volume":"3","author":"M Hudecek","year":"2015","unstructured":"Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res. 2015;3:125\u201335.","journal-title":"Cancer Immunol Res"},{"key":"6131_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC Van Der Stegen","year":"2015","unstructured":"Van Der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499\u2013509.","journal-title":"Nat Rev Drug Discov"},{"key":"6131_CR17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/mt.2009.83","volume":"17","author":"MC Milone","year":"2009","unstructured":"Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-desnoyers G, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased Antileukemic efficacy in vivo. Mol Ther. 2009;17:1453\u201364.","journal-title":"Mol Ther"},{"key":"6131_CR18","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0813101106","volume":"106","author":"C Carpenito","year":"2009","unstructured":"Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-rohena A, Haines KM, Heitjan DF, Albelda SM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. PNAS. 2009;106:3360\u20135.","journal-title":"PNAS"},{"key":"6131_CR19","doi-asserted-by":"crossref","unstructured":"Guillermo L. Chantada, Jorge Rossi, Fernando Casco, Fandin A, Marcelo Scopinaro, \n                    MariaT.G.de\n                    \n                   Da\u2019vila, Abramson DH: An aggressive bone marrow evaluation including immunocytology with gd2 for advanced retinoblastoma. J Pediatr Hematol Oncol 2006, 28(6):369\u2013373.","DOI":"10.1097\/00043426-200606000-00009"},{"key":"6131_CR20","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ijc.2910530614","volume":"53","author":"J Portoukalian","year":"1993","unstructured":"Portoukalian J, David M-J, Gain P, Richard M. Shedding of GD2 ganglioside in patients with retinoblastoma. Int J Cancer. 1993;53:948\u201351.","journal-title":"Int J Cancer"},{"issue":"2","key":"6131_CR21","first-page":"253","volume":"3","author":"VE Laurent","year":"2010","unstructured":"Laurent VE, Otero LL, Vazquez V, Camarero S, Gabri MR, Labraga M, De Davila MT, Chantada GL, Alonso DF. Optimization of molecular detection of GD2 synthase mRNA in retinoblastoma. Mol Med Rep. 2010;3(2):253\u20139.","journal-title":"Mol Med Rep"},{"key":"6131_CR22","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cncr.28461","volume":"120","author":"M Roth","year":"2014","unstructured":"Roth M, Linkowski M, Tarim J, Piperdi S, Sowers R, Geller D, Gill J, Gorlick R. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548\u201354.","journal-title":"Cancer"},{"key":"6131_CR23","doi-asserted-by":"publisher","first-page":"24884","DOI":"10.18632\/oncotarget.4670","volume":"6","author":"M Prapa","year":"2015","unstructured":"Prapa M, Caldrer S, Spano C, Bestagno M, Golinelli G, Grisendi G, Petrachi T, Conte P, Horwitz EM, Campana D, et al. A novel anti-GD2\/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget. 2015;6:24884\u201394.","journal-title":"Oncotarget"},{"key":"6131_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1517\/14728222.2014.986459","volume":"19","author":"M Suzuki","year":"2015","unstructured":"Suzuki M, Cheung N-KV. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets. 2015;19:349\u201362.","journal-title":"Expert Opin Ther Targets"},{"key":"6131_CR25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","volume":"363","author":"AL Yu","year":"2010","unstructured":"Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, Interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324\u201334.","journal-title":"N Engl J Med"},{"key":"6131_CR26","unstructured":"Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF: Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985, 45:2642\u20132649 ST - Monoclonal antibodies to a glycolipid."},{"issue":"5","key":"6131_CR27","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1586\/17512433.2016.1160775","volume":"9","author":"J Mora","year":"2016","unstructured":"Mora J. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Rev Clin Pharmacol. 2016;9(5):647\u201353.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"6131_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nn1827","volume":"10","author":"PF Maness","year":"2007","unstructured":"Maness PF, Schachner M. Neural recognition molecules of the immunoglobulin superfamily: signaling transducers of axon guidance and neuronal migration. Nat Neurosci. 2007;10(1):19\u201326.","journal-title":"Nat Neurosci"},{"key":"6131_CR29","doi-asserted-by":"crossref","first-page":"15441","DOI":"10.18632\/oncotarget.14487","volume":"8","author":"DH Jo","year":"2017","unstructured":"Jo DH, Lee K, Kim JH, Jun HO, Kim Y, Cho Y-L, Yu YS, Min J-K, Kim JH. L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma. Oncotarget. 2017;8:15441\u201352.","journal-title":"Oncotarget"},{"issue":"9387","key":"6131_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0140-6736(03)14342-5","volume":"362","author":"M Fogel","year":"2003","unstructured":"Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P. L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet (London, England). 2003;362(9387):869\u201375.","journal-title":"Lancet (London, England)"},{"issue":"5","key":"6131_CR31","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1245\/s10434-006-9281-8","volume":"14","author":"YJ Boo","year":"2007","unstructured":"Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol. 2007;14(5):1703\u201311.","journal-title":"Ann Surg Oncol"},{"issue":"34","key":"6131_CR32","doi-asserted-by":"publisher","first-page":"55276","DOI":"10.18632\/oncotarget.10527","volume":"7","author":"S Inaguma","year":"2016","unstructured":"Inaguma S, Wang Z, Lasota JP, Miettinen MM. Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: an immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors. Oncotarget. 2016;7(34):55276\u201389.","journal-title":"Oncotarget"},{"key":"6131_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","volume":"23","author":"A K\u00fcnkele","year":"2017","unstructured":"K\u00fcnkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, Chang CA, Rolczynski LS, Brown C, Mgebroff S, et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin Cancer Res. 2017;23:466\u201377.","journal-title":"Clin Cancer Res"},{"key":"6131_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF00295364","volume":"70","author":"J Squire","year":"1985","unstructured":"Squire J, Gallie BL, Phillips RA. A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Hum Genet. 1985;70:291\u2013301.","journal-title":"Hum Genet"},{"issue":"1","key":"6131_CR35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ijc.2910460123","volume":"46","author":"Sahine Griegel","year":"1990","unstructured":"Griegel S, Hong C, Fr\u00f6tschel R, H\u00fclawe DF, Horsthemke B, Rajewski MF: Newly established human retinoblastoma cell lines exhibit an \"immortalized\" but not an invasive phenotype in vitro. Int J Cancer 1990, 46:125\u2013132.","journal-title":"International Journal of Cancer"},{"key":"6131_CR36","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","volume":"3","author":"A Kunkele","year":"2015","unstructured":"Kunkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res. 2015;3:368\u201379.","journal-title":"Cancer Immunol Res"},{"key":"6131_CR37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ijc.1457","volume":"94","author":"C Rossig","year":"2001","unstructured":"Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94:228\u201336.","journal-title":"Int J Cancer"},{"key":"6131_CR38","first-page":"32","volume":"10","author":"LJ Ausubel","year":"2012","unstructured":"Ausubel LJ, Hall C, Sharma A, Shakeley R, Lopez P, Quezada V, Couture S, Laderman K, McMahon R, Huang P, et al. Production of CGMP-grade lentiviral vectors. BioProcess International. 2012;10:32\u201343.","journal-title":"BioProcess International"},{"key":"6131_CR39","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/gt.2010.91","volume":"17","author":"A Hombach","year":"2010","unstructured":"Hombach A, Abken H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response. Gene Ther. 2010;17:1206\u201313.","journal-title":"Gene Ther"},{"key":"6131_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"6131_CR41","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD. Cancer Immunoediting : integrating suppression and promotion. Science. 2011;331:1565\u201371.","journal-title":"Science"},{"key":"6131_CR42","first-page":"1324","volume":"14","author":"CU Louis","year":"2011","unstructured":"Louis CU, Savoldo B, Dotti G, Ma P, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E, et al. Antitumor activity and long-term fate of chimeric antigen receptor \u2013 positive T cells in patients with neuroblastoma. Blood. 2011;14:1324\u201334.","journal-title":"Blood"},{"issue":"1","key":"6131_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","volume":"155","author":"GL Beatty","year":"2018","unstructured":"Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, et al. Activity of Mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 2018;155(1):29\u201332.","journal-title":"Gastroenterology"},{"issue":"26","key":"6131_CR44","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561\u20139.","journal-title":"N Engl J Med"},{"key":"6131_CR45","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2015","unstructured":"Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, et al. Target antigen density governs the efficacy of anti\u2013CD20-CD28-CD3 \u03b6 chimeric antigen receptor\u2013modified effector CD8 T cells. J Immunol. 2015;194:911\u201320.","journal-title":"J Immunol"},{"key":"6131_CR46","doi-asserted-by":"publisher","first-page":"10160","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJS, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Staci M, Delbrook C, Yates B, et al. CD22-CAR T cells induce remissions in CD19-CAR Na\u00efve and resistant B-ALL. Nat Med. 2018;24:10160\u20133.","journal-title":"Nat Med"},{"issue":"7","key":"6131_CR47","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/CJI.0b013e3180de5d90","volume":"30","author":"F Turatti","year":"2007","unstructured":"Turatti F, Figini M, Balladore E, Alberti P, Casalini P, Marks JD, Canevari S, Mezzanzanica D. Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction. J Immunother. 2007;30(7):684\u201393.","journal-title":"J Immunother"},{"issue":"5","key":"6131_CR48","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"2","key":"6131_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, Patel PR, Guedan S, Scholler J, Keith B, et al. Distinct signaling of Coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390.","journal-title":"Immunity"},{"key":"6131_CR50","doi-asserted-by":"crossref","unstructured":"Hudecek M, Lupo-Stanghellini M-T, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013.","DOI":"10.1158\/1078-0432.CCR-13-0330"},{"key":"6131_CR51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, Cook DR, Thokala R, Blouch K, McGettigan-Croce B, et al. Checkpoint blockade reverses Anergy in IL-13Ralpha2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018;11:20\u201338.","journal-title":"Mol Ther Oncolytics"},{"key":"6131_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991\u20138.","journal-title":"Nat Immunol"},{"issue":"5","key":"6131_CR53","doi-asserted-by":"publisher","first-page":"e215","DOI":"10.3324\/haematol.2017.183459","volume":"103","author":"Haneen Shalabi","year":"2018","unstructured":"Shalabi H, Kraft IL, Wang H-W, Yuan CM, Yates B, Delbrook C, Zimbelman JD, Giller R, Stetler-Stevenson M, Jaffe ES et al: Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 2018, 103:haematol.2017.183459.","journal-title":"Haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6131-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6131-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:10:38Z","timestamp":1599520238000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6131-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,9]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6131"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6131-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,9]]},"assertion":[{"value":"8 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Patients or their guardian (for participants under the age of 16\u2009years) had given written consent and research was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the University of Duisburg-Essen ethics committee (13\u20135405-BO).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or non-financial competing interests to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"895"}}